MedTrace Logo

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

NCT05682170 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-09-19

No results posted yet for this study

Summary

A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia (AML).

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

DRUG

ZN-d5 ZN-c3

Oral agent

DRUG

ZN-c3

Oral agent

Sponsors & Collaborators

  • K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • K-Group Alpha, Inc. a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. · K-Group Alpha

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-07-02
Completion
2024-07-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05682170 on ClinicalTrials.gov